PMID- 22321067
OWN - NLM
STAT- MEDLINE
DCOM- 20120516
LR  - 20211021
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 103
IP  - 4
DP  - 2012 Apr
TI  - Immunological evaluation of personalized peptide vaccination in refractory small 
      cell lung cancer.
PG  - 638-44
LID - 10.1111/j.1349-7006.2012.02202.x [doi]
AB  - Since the prognosis of small cell lung cancer (SCLC) remains poor, development of 
      new therapeutic approaches, including immunotherapies, would be desirable. In the 
      current study, to evaluate immunological responses in refractory SCLC patients, 
      we conducted a small scale phase II clinical trial of personalized peptide 
      vaccination (PPV), in which vaccine antigens are selected based on pre-existing 
      host immunity. Ten refractory SCLC patients, who had failed to respond to chemo- 
      and/or chemoradiotherapies (median number of regimens, 2.5; median duration, 20.5 
      months), were enrolled. A maximum of four human leukocyte antigen (HLA)-matched 
      peptides showing higher antigen-specific humoral responses were subcutaneously 
      administered (weekly for six consecutive weeks and then bi-weekly thereafter). 
      PPV was terminated before the 3rd administration in four patients because of 
      rapid disease progression, whereas the remaining six patients completed at least 
      one cycle (six times) of vaccinations. Peptide-specific immunological boosting 
      was observed in all of the six patients at the end of the first cycle of 
      vaccinations, with their survival time of 25, 24.5 (alive), 10 (alive), 9.5, 6.5, 
      and 6 months. Number of previous chemotherapy regimens and frequency of CD3(+) 
      CD26(+) cells in peripheral blood were potentially prognostic in the vaccinated 
      patients (hazard ratio [HR] = 2.540, 95% confidence interval [CI] = 1.188-5.431, 
      P = 0.016; HR = 0.941, 95% CI = 0.878-1.008, P = 0.084; respectively). Based on 
      the feasible immune responses in refractory SCLC patients who received at least 
      one cycle (six times) of vaccinations, PPV could be recommended for a next stage 
      of larger-scale, prospective clinical trials.
CI  - (c) 2012 Japanese Cancer Association.
FAU - Terazaki, Yasuhiro
AU  - Terazaki Y
AD  - Department of Surgery, Kurume University School of Medicine, Kurume, Japan.
FAU - Yoshiyama, Koichi
AU  - Yoshiyama K
FAU - Matsueda, Satoko
AU  - Matsueda S
FAU - Watanabe, Noriko
AU  - Watanabe N
FAU - Kawahara, Akihiko
AU  - Kawahara A
FAU - Naito, Yoshiki
AU  - Naito Y
FAU - Suekane, Shigetaka
AU  - Suekane S
FAU - Komatsu, Nobukazu
AU  - Komatsu N
FAU - Ioji, Tetsuya
AU  - Ioji T
FAU - Yamada, Akira
AU  - Yamada A
FAU - Mine, Takashi
AU  - Mine T
FAU - Terasaki, Mizuhiko
AU  - Terasaki M
FAU - Itoh, Kyogo
AU  - Itoh K
FAU - Takamori, Shinzo
AU  - Takamori S
FAU - Sasada, Tetsuro
AU  - Sasada T
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120213
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (CD3 Complex)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Vaccines, Subunit)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
SB  - IM
MH  - Aged
MH  - CD3 Complex
MH  - Cancer Vaccines/adverse effects/*immunology/therapeutic use
MH  - Dipeptidyl Peptidase 4
MH  - Humans
MH  - Lung Neoplasms/*therapy
MH  - Lymphocyte Subsets/immunology
MH  - Lymphocytes, Tumor-Infiltrating/immunology
MH  - Male
MH  - Middle Aged
MH  - Small Cell Lung Carcinoma/*therapy
MH  - Vaccines, Subunit/*immunology/therapeutic use
PMC - PMC7659229
EDAT- 2012/02/11 06:00
MHDA- 2012/05/17 06:00
PMCR- 2012/04/01
CRDT- 2012/02/11 06:00
PHST- 2011/09/02 00:00 [received]
PHST- 2011/12/16 00:00 [revised]
PHST- 2011/12/25 00:00 [accepted]
PHST- 2012/02/11 06:00 [entrez]
PHST- 2012/02/11 06:00 [pubmed]
PHST- 2012/05/17 06:00 [medline]
PHST- 2012/04/01 00:00 [pmc-release]
AID - CAS2202 [pii]
AID - 10.1111/j.1349-7006.2012.02202.x [doi]
PST - ppublish
SO  - Cancer Sci. 2012 Apr;103(4):638-44. doi: 10.1111/j.1349-7006.2012.02202.x. Epub 
      2012 Feb 13.